Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Acorda Therapeutics
Age
25–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eligible subjects will be men or women in good general health with a diagnosis of mild or moderate asthma;
On a stable regimen of asthma medications for at least 30 days prior to screening;
Body mass index (BMI) 18 to 32 kg/m2;
Forced expiratory volume in one second (FEV1) ≥60% of predicted for race, age, sex, and height;
FEV1/FVC (forced vital capacity) ratio ≥70%.
You may not be if
More than 2 hospitalizations or emergency room visits, or more than 3 courses of systemic steroids in the past 12 months or 1 course within the past 8 weeks for respiratory illness;
Asthma exacerbation within 8 weeks before screening;
Unscheduled or urgent visit to any medical facility for asthma-related problems within 8 weeks before screening;
History of intubation or intensive care unit admission for asthma in the past 5 years;
History of chronic obstructive pulmonary disorder (COPD) requiring intermittent or continuous use of any oral or inhaled medication therapy within last 3 years;
Renal impairment as defined by a calculated creatinine clearance of ≤ 80 mL/minute.
Clareo Health | A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma
